Gaucher's disease: past, present and future (Q40867344)

24 September 2017

1 reference

title

Gaucher's disease: past, present and future (English)

1 reference

24 September 2017

1 reference

Brady RO

1

1 reference

24 September 2017

1 December 1997

1 reference

Best Practice and Research: Clinical Haematology

24 September 2017

1 reference

24 September 2017

10

1 reference

24 September 2017

4

1 reference

24 September 2017

621-634

1 reference

Assignment of the gene coding for human beta-glucocerebrosidase to the region q21-q31 of chromosome 1 using monoclonal antibodies

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

1 reference

7 January 2021

Enzyme replacement therapy for Gaucher disease: critical investigations beyond demonstration of clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Identification of heterozygous carriers of lipid storage diseases. Current status and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Expression of human glucocerebrosidase in long-term reconstituted mice following retroviral-mediated gene transfer into hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Enzyme Augmentation in Moderate to Life-Threatening Gaucher Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Isolation of cDNA clones for human beta-glucocerebrosidase using the lambda gt11 expression system

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

MRI of multiple platyspondyly in Gaucher disease: response to enzyme replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Diagnosis of gaucher's disease and niemann-pick disease with small samples of venous blood

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Infantile (type II) Gaucher's disease: in utero diagnosis and fetal pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

Cerebroside synthesis in Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

The lysosomal localization of sphingolipid hydrolases

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980031-5

7 January 2021

10.1016/S0950-3536(97)80031-5

Identifiers

DOI

1 reference

24 September 2017

1 reference

PubMed ID

9497855